Dr. Reddy’s Laboratories has announced a voluntary recall of a specific batch of Levetiracetam 0.75% Sodium Chloride Injection in the United States. The affected batch, which is identified by the Lot Number A1540076, is a single-dose infusion bag with a label discrepancy. The bag is mistakenly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, whereas the aluminum overwrap packaging correctly identifies it as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.
The recall is being conducted to ensure patient safety and minimize the risk of medication errors. Patients and healthcare providers are advised to stop using the affected product immediately and return it to the supplier or other designated facilities for proper disposal.
The recall is a consumer-level recall, which means that patients who have already received the product are being affected. However, the company is taking steps to ensure that the issue is resolved and that patients and healthcare providers are aware of the correct product labeling.
The recall is expected to have a minimal impact on the company’s financial performance, as it is a one-off issue and the company has sufficient processes in place to correct the problem.
This recall is a rare instance of a labeling issue, and the company is taking steps to ensure that it does not happen again in the future. The company’s commitment to quality and patient safety is evident in its swift and transparent handling of this situation.
In conclusion, the recall is a precautionary measure to ensure patient safety, and it is essential for patients and healthcare providers to be aware of the correct product labeling. Dr. Reddy’s Laboratories is taking steps to rectify the issue and ensure that it does not happen again in the future.